Drug Profile
Research programme: anti-infectives - Roche/SGX Pharmaceuticals
Latest Information Update: 21 Feb 2017
Price :
$50
*
At a glance
- Originator Anadys Pharmaceuticals; SGX Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 14 Jun 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 31 Aug 2005 Structural GenomiX is now called SGX Pharmaceuticals
- 26 Feb 2002 Preclinical trials in Bacterial infections in USA (unspecified route)